COVID-19
Showing NaN - NaN of 55
COVID-19, Vaccine Trial in Baltimore (REDES, Control)
Recruiting
- COVID-19
- Vaccine
- REDES
- Control
-
Baltimore, MarylandJohns Hopkins University
Nov 10, 2023
COVID-19, Infectious Disease, Symptomatic COVID-19 Infection Laboratory-Confirmed Trial in United States (RQ-001, Placebo)
Recruiting
- COVID-19
- +3 more
- RQ-001
- Placebo
-
Cullman, Alabama
- +8 more
Sep 28, 2023
COVID-19 Trial in United States (XBB.1.5 Vaccine (Booster), XBB.1.5 Vaccine (single dose))
Not yet recruiting
- COVID-19
- XBB.1.5 Vaccine (Booster)
- XBB.1.5 Vaccine (single dose)
-
Mobile, Alabama
- +29 more
Aug 4, 2023
COVID-19, COVID Long-Haul Trial in Baltimore (Magnetic Resonance Imaging, Ultra-High Resolution Computed Tomography (CT) Scan)
Enrolling by invitation
- COVID-19
- COVID Long-Haul
- Magnetic Resonance Imaging
- Ultra-High Resolution Computed Tomography (CT) Scan
-
Baltimore, MarylandJohns Hopkins School of Medicine
Jun 23, 2023
COVID-19 Trial in Baltimore (Emetine Hydrochloride, Placebo)
Not yet recruiting
- COVID-19
- Emetine Hydrochloride
- Placebo
-
Baltimore, MarylandJohns Hopkins University, The Center for TB and AIDS Research
Jun 9, 2023
COVID-19 Trial in Worldwide (BRII-196, BRII-198, Placebo)
Completed
- COVID-19
- BRII-196
- +3 more
-
Tucson, Arizona
- +106 more
Mar 24, 2023
COVID-19 Trial in Worldwide (AZD7442, Placebo, Remdesivir)
Active, not recruiting
- COVID-19
- AZD7442
- +2 more
-
Tucson, Arizona
- +123 more
Mar 24, 2023
COVID-19 Trial in Worldwide (LY3819253, Placebo, Remdesivir)
Completed
- COVID-19
- LY3819253
- +2 more
-
Tucson, Arizona
- +56 more
Mar 22, 2023
COVID-19 Trial in Worldwide (VIR-7831, Placebo, Remdesivir)
Completed
- COVID-19
- VIR-7831
- +2 more
-
Tucson, Arizona
- +104 more
Mar 22, 2023
COVID-19 Trial in Baltimore (Intervention test)
Enrolling by invitation
- COVID-19
- Intervention test
-
Baltimore, MarylandJohns Hopkins Bloomberg School of Public Health
Mar 13, 2023
Vaccination Refusal, COVID-19 Trial in Baltimore (Factual messages, Narrative message, Mixed message)
Completed
- Vaccination Refusal
- COVID-19
- Factual messages
- +2 more
-
Baltimore, MarylandJohns Hopkins Bloomberg School of Public Health
Mar 1, 2023
SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in
Recruiting
- COVID-19
-
Baltimore, Maryland
- +1 more
Feb 2, 2023
B- and T-cell Repertoire and Immune Response in Acute and
Recruiting
- COVID-19
-
Washington, District of Columbia
- +3 more
Jan 24, 2023
COVID-19, Coronavirus, SARS-CoV-2 Trial in United States (pathogen reduced SARS-CoV-2 convalescent plasma, Placebo)
Completed
- COVID-19
- +2 more
- pathogen reduced SARS-CoV-2 convalescent plasma
- Placebo
-
Little Rock, Arkansas
- +25 more
Oct 6, 2022
Infection Viral, Thromboses, Venous, COVID-19 Trial in United States (Enoxaparin Prefilled Syringe [Lovenox])
Completed
- Infection Viral
- +2 more
- Enoxaparin Prefilled Syringe [Lovenox]
-
Birmingham, Alabama
- +15 more
Sep 15, 2022
SARS-CoV Infection, COVID-19, Allergic Reaction Trial in United States (Moderna COVID-19 Vaccine, Pfizer-BioNTech COVID-19
Completed
- SARS-CoV Infection
- +3 more
- Moderna COVID-19 Vaccine
- +2 more
-
Tucson, Arizona
- +28 more
Sep 19, 2022
COVID-19 Trial in United States (Ad26.COV2.S, BNT162b2, mRNA-1273)
Recruiting
- COVID-19
- Ad26.COV2.S
- +4 more
-
Atlanta, Georgia
- +11 more
Aug 11, 2022
Intensive Care Survivors of Coronavirus Disease (COVID-19)
Recruiting
- COVID-19
-
Baltimore, Maryland
- +1 more
Aug 8, 2022
COVID-19, SARS-CoV-2 Trial in Chile, Peru, United States (AZD1222, Placebo)
Active, not recruiting
- COVID-19
- SARS-CoV-2
- AZD1222
- Placebo
-
Phoenix, Arizona
- +83 more
Jul 13, 2022
SARS-CoV-2 Infection, COVID-19 Trial in Worldwide (BNT162b2, Placebo, BNT162b2 OMI)
Recruiting
- SARS-CoV-2 Infection
- COVID-19
- BNT162b2
- +4 more
-
Athens, Alabama
- +158 more
Jul 18, 2022
SARS-CoV-2 Specific CD8 T Cells in Humans
Recruiting
- COVID-19
-
Baltimore, MarylandNational Institute of Aging, Clinical Research Unit
Jul 6, 2022